Aaron Wealth Advisors LLC Has $1.31 Million Stock Position in Astrazeneca Plc $AZN

Aaron Wealth Advisors LLC reduced its stake in Astrazeneca Plc (NYSE:AZN) by 76.3% in the first quarter, HoldingsChannel reports. The institutional investor owned 6,644 shares of the company’s stock after selling 21,340 shares during the quarter. Aaron Wealth Advisors LLC’s holdings in Astrazeneca were worth $1,310,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of AZN. TD Asset Management Inc boosted its stake in shares of Astrazeneca by 20.0% in the 3rd quarter. TD Asset Management Inc now owns 1,089,612 shares of the company’s stock worth $83,595,000 after buying an additional 181,273 shares during the last quarter. US Bancorp DE increased its position in shares of Astrazeneca by 6.6% during the third quarter. US Bancorp DE now owns 242,181 shares of the company’s stock valued at $18,581,000 after acquiring an additional 15,065 shares during the last quarter. Natixis Advisors LLC increased its position in shares of Astrazeneca by 14.3% during the third quarter. Natixis Advisors LLC now owns 2,100,390 shares of the company’s stock valued at $161,142,000 after acquiring an additional 262,465 shares during the last quarter. Guardian Capital LP lifted its holdings in Astrazeneca by 31.0% during the third quarter. Guardian Capital LP now owns 83,074 shares of the company’s stock worth $6,373,000 after acquiring an additional 19,648 shares during the period. Finally, Legacy Capital Group California Inc. purchased a new position in Astrazeneca in the third quarter worth $406,000. 20.35% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on AZN shares. Wall Street Zen upgraded shares of Astrazeneca from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Morgan Stanley reaffirmed an “overweight” rating on shares of Astrazeneca in a research report on Wednesday, April 8th. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Astrazeneca in a research note on Tuesday, June 9th. Sanford C. Bernstein restated a “buy” rating on shares of Astrazeneca in a research note on Monday, May 4th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Astrazeneca in a report on Wednesday, March 18th. Twelve investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Astrazeneca has an average rating of “Moderate Buy” and a consensus price target of $205.33.

Astrazeneca Stock Performance

NYSE:AZN opened at $188.58 on Friday. The company has a market capitalization of $292.47 billion, a price-to-earnings ratio of 28.32, a PEG ratio of 1.61 and a beta of 0.25. The business has a 50 day moving average of $184.66 and a 200 day moving average of $186.93. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71. Astrazeneca Plc has a 1-year low of $137.23 and a 1-year high of $212.71.

Astrazeneca (NYSE:AZN) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.52 by $0.06. The firm had revenue of $15.29 billion during the quarter, compared to the consensus estimate of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. On average, sell-side analysts predict that Astrazeneca Plc will post 9.39 earnings per share for the current fiscal year.

Astrazeneca Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.